2021
DOI: 10.3390/ijms221910870
|View full text |Cite
|
Sign up to set email alerts
|

LEF1 Enhances the Progression of Colonic Adenocarcinoma via Remodeling the Cell Motility Associated Structures

Abstract: Lymphoid enhancer-binding factor 1 (LEF1) is a key transcription factor mediating the Wnt signaling pathway. LEF1 is a regulator that is closely associated with tumor malignancy and is usually upregulated in cancers, including colonic adenocarcinoma. The underlying molecular mechanisms of LEF1 regulation for colonic adenocarcinoma progression remain unknown. To explore it, the LEF1 expression in caco2 cells was inhibited using an shRNA approach. The results showed that downregulation of LEF1 inhibited the mali… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
9
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 39 publications
1
9
1
Order By: Relevance
“…The various anticancer effects of juglone indicate it has the potential to become an anticancer drug. However, due to the biological toxicity of juglone, it is necessary to modify its chemical structure to improve bioavailability and reduce its toxicity [28]. In addition, novel drug delivery systems, such as liposome encapsulation, may be an appropriate method to improve juglone pharmacokinetic properties [29].…”
Section: Discussionmentioning
confidence: 99%
“…The various anticancer effects of juglone indicate it has the potential to become an anticancer drug. However, due to the biological toxicity of juglone, it is necessary to modify its chemical structure to improve bioavailability and reduce its toxicity [28]. In addition, novel drug delivery systems, such as liposome encapsulation, may be an appropriate method to improve juglone pharmacokinetic properties [29].…”
Section: Discussionmentioning
confidence: 99%
“…LEF1 contains a β-catenin-binding domain, a context-dependent regulatory domain, a high-mobility group DNA-binding domain (HMG), and a nuclear localization sequence 38. There is evidence that LEF1 can induce epithelial-mesenchymal transition (EMT) in the absence of β-catenin, potentially via its HMG domain 39,40. LEF1 also responds to Notch, and the effects do not appear to depend on Wnt signaling components 41.…”
Section: Discussionmentioning
confidence: 99%
“…STRING analysis also revealed the complex interaction of CTNNB1, Sox 17, 30, LEF1, and TCF7L1 in beta-catenin binding. LEF1 (lymphoid enhancer-binding factor 1) shares significant homology with HMG protein and are involved in Wnt canonical pathway, cell differentiation, and follicle morphogenesis (Xiao et al, 2021). Pax3, Sox10, and c-Ret are components of a neural crest development pathway, and interruption of this pathway at various stages results in neural crest–related human genetic syndromes (Lang et al, 2000)…”
Section: Discussionmentioning
confidence: 99%